1

# 1 Comparative and Integrated Analysis of Plasma Extracellular Vesicles Isolations

# 2 Methods in Healthy Volunteers and Patients Following Myocardial Infarction

- 3 Short title: Integrated Analysis of Plasma Extracellular Isolation Methods
- 4 Daan Paget<sup>1,2</sup>, Antonio Checa<sup>3</sup>, Benedikt Zöhrer<sup>4,5</sup>, Raphael Heilig<sup>6</sup>, Mayooran
- 5 Shanmuganathan<sup>1,7</sup>, Raman Dhaliwal<sup>8</sup>, Errin Johnson<sup>8</sup>, Maléne Møller Jørgensen<sup>9,10</sup>, Rikke
- 6 Bæk<sup>9</sup>, Oxford Acute Myocardial Infarction Study (OxAMI)<sup>1,7</sup>, Craig E. Wheelock<sup>3,5,11</sup>, Keith M.
- 7 Channon<sup>1,7</sup>, Roman Fischer<sup>6</sup>, Daniel C. Anthony<sup>2</sup>, Robin P. Choudhury<sup>1,7</sup> and Naveed
- 8 Akbar<sup>1</sup>.
- <sup>1</sup> Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of
   Oxford, Oxford, United Kingdom.
- <sup>2</sup> Department of Pharmacology, University of Oxford, Oxford, United Kingdom.
- <sup>3</sup> Unit of Integrative Metabolomics, Institute of Environmental Medicine, Karolinska Institute,
   Stockholm, Sweden.
- <sup>4</sup> Respiratory Medicine Unit, Department of Medicine Solna and Center for Molecular
   Medicine, Karolinska Institutet, Stockholm, Sweden.
- <sup>5</sup> Department of Respiratory Medicine and Allergy, Karolinska University Hospital,
   Stockholm, Sweden.
- <sup>6</sup> Target Discovery Institute, Centre for Medicines Discovery, Nuffield Department of
   Medicine, University of Oxford, Oxford, United Kingdom.
- <sup>7</sup> Acute Vascular Imaging Centre, Radcliffe Department of Medicine, University of
- 21 Oxford, United Kingdom.
- <sup>8</sup> Sir William Dunn School of Pathology, University of Oxford, Oxford, United Kingdom.
- <sup>9</sup> Department of Clinical Immunology, Aalborg University Hospital, Aalborg, Denmark.
- <sup>10</sup> Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
- <sup>11</sup> Gunma University Initiative for Advanced Research (GIAR), Gunma University, Showamachi, Maebashi, Gunma, Japan.
- 27

28 Word Count: 11,258

- 29 Number of Figures: 8
- 30 \*Corresponding Author: Dr Naveed Akbar
- 31 E-mail: Naveed.Akbar@cardiov.ox.ac.uk
- 32 Telephone Number: 01865 234902
- 33 Address: Division of Cardiovascular Medicine, Radcliffe Department of Medicine, John
- Radcliffe Hospital, Level 6, West Wing, OX3 9DU, United Kingdom.

35

36

#### 37 Abstract

38 Plasma extracellular vesicle (EV) number and composition are altered following myocardial 39 infarction (MI), but to properly understand the significance of these changes it is essential to 40 appreciate how the different isolation methods affect EV characteristics, proteome and 41 sphingolipidome. Here, we compared plasma EV isolated from platelet-poor plasma from 42 four healthy donors and six MI patients at presentation and 1-month post-MI using 43 ultracentrifugation, polyethylene glycol precipitation, acoustic trapping, size-exclusion 44 chromatography (SEC) or immunoaffinity capture. The isolated EV were evaluated by 45 Nanoparticle Tracking Analysis, Western blot, transmission electron microscopy, an EV-46 protein array, untargeted proteomics (LC-MS/MS) and targeted sphingolipidomics (LC-47 MS/MS). The application of the five different plasma EV isolation methods in patients presenting with MI showed that the choice of plasma EV isolation method influenced the 48 49 ability to distinguish elevations in plasma EV concentration following MI, enrichment of EV-50 cargo (EV-proteins and sphingolipidomics) and associations with the size of the infarct 51 determined by cardiac magnetic resonance imaging 6 months-post-MI. Despite the selection 52 bias imposed by each method, a core of EV associated proteins and lipids was detectable 53 using all approaches. However, this study highlights how each isolation method comes with 54 its own idiosyncrasies and makes the comparison of data acquired by different techniques in 55 clinical studies problematic.

56

#### 57 Key words

58 Ultracentrifugation, size exclusion chromatography, precipitation, acoustic trapping,
59 immunoaffinity capture, plasma, omics, human.

60

3

### 61 Introduction

Plasma extracellular vesicles (EV) are increased in number and carry altered protein, lipid and RNA cargo in the peripheral blood in many pathologies [1-6]. Analysis of plasma EV by omics approaches may provide unparalleled insight into multiple disease mechanisms and disease monitoring in patients for personalized medicine. However, it is unclear how different plasma EV isolation methods influence the plasma EV-profile or the so-called 'EV-signature' in patients.

68

69 Current methods for the isolation of heterogeneous plasma EV include: ultracentrifugation 70 (UC), density ultracentrifugation, field-flow fractionation, size-exclusion chromatography (SEC), precipitation, acoustic trapping [7] and immunoaffinity capture [8]. However, 71 72 unsurprisingly, laborious protocols that yield pure EV from plasma are less well favoured in 73 large cohorts [9, 10] than protocols that are easier, lower cost, and more convenient. These 74 methodological predilections are further impacted by the availability of stored biobank 75 plasma, which often carry contaminating erythrocytes, immune cells, and platelets [11]. 76 Irrespective of pre-storage processing, all plasma is a rich source of lipoproteins 77 (apolipoprotein A and B), albumin, globulins and fibrinogens, which can co-isolate with 78 plasma EV. The proportion of these cell-derived and non-cellular contaminants in the purified 79 sample is method-dependent [12] and they may obscure EV associated cargo [13, 14].

80

81 Comparative isolation studies for plasma EV often assess EV size and concentration by 82 Nanoparticle Tracking Analysis (NTA) and morphology by transmission electron microscopy 83 (TEM). EV markers are usually evaluated using western blot or flow cytometry [15-18]. 84 These standard analyses are often driven by the requirements of scientific bodies and 85 consensus statements, which might be considered too prescriptive and refractory to change 86 as our understanding of EV biology evolves [14]. However, additional assessments of how 87 isolation methods influence the plasma EV preparation have been explored with a range of 88 techniques, including proteomics [16, 18-21], profiling of cytokines [22], RNA integrity [23,

4

89 24], lipidomics [25], flow cytometry [15, 26] or a combination of these methods [16].
90 However, the wide range of plasma EV isolation and characterization techniques has
91 evolved largely in the absence of systematic method characterization comparisons. As a
92 consequence, the absence of an understanding of the impact of isolation techniques has led
93 to plenty of uncertainty in relation to the interpretation of EV discoveries in clinical samples.

94

95 Here, we used platelet-free plasma from the same healthy volunteers to compare five 96 different plasma EV isolation methods including: UC, precipitation, acoustic trapping, SEC 97 and immunoaffinity capture using tetraspanins CD9, CD63 and CD81 (Figure 1). We then 98 sought to determine how plasma EV isolation methods influence EV characteristics in a set 99 of clinically well characterised individuals. Acute myocardial infarction (MI) is an important 100 pathology; it is also an example of sterile inflammation where plasma EV number and 101 composition are acutely altered [5, 6]. Plasma EV from MI patients at two different time 102 points were isolated using the five different EV isolation methods (Figure 1). Integrated 103 unsupervised analysis of all the acquired characterization data from the five different 104 methods was used to identify the similarities and differences between each method and to 105 highlight how each technique might influence the protein and sphingolipid composition.

#### 106 Materials and Methods

# 107 Healthy Volunteers and Acute Myocardial Infarction Patients.

All human investigations were conducted in accordance with the Declaration of Helsinki. The Oxfordshire Research Ethics Committee (Ref: 08/H0603/41 and 11/SC/0397) approved the human clinical protocols. All healthy volunteers and myocardial Infarction (MI) patients provided informed written consent for inclusion in the study.

112

### 113 Generation of Platelet Poor Plasma

Platelet-poor plasma was generated from healthy volunteers (N=4), patients presenting with MI (N=6) and from the same patients 1-month post-MI. 10-20 mL of whole blood was collected in EDTA (Greiner Bio-One, Stonehouse, United Kingdom) coated tubes and centrifuged at 1,000 x g for 25 minutes. The plasma was collected and centrifuged again for 10 minutes at 5,000 x g to produce platelet-poor plasma. The platelet-poor plasma was stored in 500  $\mu$ L aliguots at -80 °C for future use.

120

### 121 Isolation of plasma EV using UC

122 Plasma aliquots were thawed at room temperature and EV were isolated by UC by 123 transferring 500 µL of platelet-poor plasma from healthy volunteers or 100 µL from platelet-124 poor plasma from MI patients to a 13.2 mL QuickSeal tube (Beckman Coulter, California, 125 United States). The tubes were filled with a 16 G hypodermic needles (Microlance, VWR, 126 Pennsylvania, United States) fitted to a 10 mL syringe (VWR, Pennsylvania, United States) 127 and after plasma was injected into the tube, 13 mL of phosphate buffered saline (PBS, 128 Thermo Fischer Scientific, Massachusetts, United States) was added. The tubes were 129 sealed using a soldering iron (Zacro, 60 W) and centrifuged using an Optima MAX-XP 130 ultracentrifuge (Beckman Coulter, California, United States) at 120,000 x g for 120 minutes 131 at 4 °C with a MLA55 fixed-angle rotor (Beckman Coulter, California, United States) [5, 6]. 132 The pelleted plasma EV were resuspended in 100 µL PBS or RIPA buffer (Thermo Fischer 133 Scientific, Massachusetts, United States) for subsequent analysis.

#### 134

# 135 Isolation of plasma EV using precipitation

136 Plasma EV were isolated by precipitation by using the Total Exosome Isolation Kit 137 (Invitrogen, Massachusetts, United States). 500 µL of platelet-poor plasma from healthy 138 volunteers or 100 µL of platelet-poor plasma from MI patients was thawed at room 139 temperature. After vortexing, 20-100 µL of the Exosome Precipitation Reagent (Total 140 Exosome Isolation Kit (for plasma), ThermoFisher Scientific, Massachusetts, United States) 141 was added and mixed by repeated pipetting. Samples were incubated for 30 minutes on ice, 142 the mixture was centrifuged at 10,000  $\times$  g for 10 minutes by a Haraeus Fresco 17 benchtop 143 centrifuge (ThermoFisher Scientific, ibid) at room temperature. The supernatant was 144 removed and samples were centrifuged again at 2,000 x g for 2 minutes to remove residual 145 supernatant. The pelleted plasma EV were resuspended in 100 µL PBS or RIPA buffer for 146 downstream analysis by repeated pipetting.

147

# 148 Isolation of plasma EV using acoustic trapping

149 Acoustic trapping of plasma for the isolation of EV was achieved by diluting plasma 1:1 with 150 PBS as previously described [18]. Briefly, samples were loaded onto a Costar 96-well plate 151 (Corning, New York, United States) and inserted in the AcouSort device (Version 2.0) 152 (AcouSort AB, Lund, Sweden). Acoustic waves were produced by a waveform generator 153 (Keysight 33210A, Keysight, California, United States) with a 9.2 V output and were directed 154 into a borosilicate capillary acoustic trapping unit (AcouSort AB, Lund, Sweden). Following 155 activation of the waveform generator and the acoustic trapping unit was initialised, 50 µL of 156 12 µm polystyrene beads (AcouSort AB, Lund, Sweden) were loaded into the acoustic 157 trapping unit using a syringe pump (Tricontinent C2400 (Tricontinent, Fürstenfeldbruck, 158 Germany) set to 50 µL/min. Each run consisted of 100 µL of 1:1 diluted plasma and were 159 loaded with a syringe pump speed of 20 µL/min. After acoustic trapping, the samples were 160 washed by aspirating 15 µL of PBS at 20 µL/min and dispensing 50 µL at 20 µL/min. After 161 the PBS wash, the samples were eluted in 50 µL of PBS and used for downstream analysis.

7

1	c	2
т	υ	2

### 163 Isolation of plasma EV using size exclusion chromatography

Size exclusion chromatography (SEC) isolation of plasma EV was achieved by using the Exo-spin<sup>™</sup> 96 (Cell Guidance Systems, Missouri, United States) [27]. Columns were equilibrated at room temperature for 15 minutes prior use. Afterwards, the columns were washed twice with 250 µL of PBS. Plasma was thawed at room temperature and 100 µL of plasma from healthy volunteers or MI patients was loaded into each column. Plasma EV were eluted by adding 200 µL of PBS to the top of the column eluted under gravity. Plasma EV were collected and stored for subsequent analysis.

171

# 172 Isolation of plasma EV using immunoaffinity capture

173 Prior to isolation, the plasma was passed through a SEC method as described above. 174 Exosome-Human CD9 Isolation Reagent, Exosome-Human CD63 Isolation/Detection 175 Reagent and Exosome-Human CD81 Isolation Reagent (all Invitrogen, Massachusetts, 176 United States) were used to capture plasma EV. The mixture was created by resuspending 177 each bead solution and mixing by repeated pipetting. Control IgG-isotype (10400C, Thermo 178 Fischer Scientific, Massachusetts, United States) matched beads were conjugated according 179 to the instructions of the Dynabeads Antibody Coupling Kit (Invitrogen, Massachusetts, United States). After SEC pre-isolation, the samples were incubated with 80 µL of the 180 181 combined CD9, CD63 and CD81 beads (end concentration 1 x  $10^7$  / mL, equal quantity of 182 each bead mixture) or equally concentrated IgG control beads at 4 °C for 18 hours under 183 continual rotation by a vertical rotor (Grant Bio, Essex, United Kingdom). After incubation, 184 the beads were pelleted for 5 minutes at room temperature using a Dynal Magnet 185 (Invitrogen, Massachusetts, United States) and the supernatant was collected for 186 subsequent analysis. Following pelleting, the samples were washed three times with 200 µL 187 of PBS and magnetic beads were pelleted as described above. Following the washes, the 188 beads were resuspended in RIPA buffer and supernatant was separated by using a 2,000 x 189 g spin and collected for subsequent analysis.

8

190
-----

191

# 192 Nanoparticle Tracking Analysis

193 Plasma EV size distribution and concentration were determined by Nanoparticle Tracking 194 Analysis (NTA) using a Zetaview device (Particle Metrix, Inning am Ammersee, Germany) as 195 previously described [5, 6]. Prior to injection into the sample chamber, samples were diluted 196 in PBS. The Zetaview measured the sample chamber from 11 positions in 2 cycles. The 197 settings were set at sensitivity 80, fame 30 and shutter speed 100. Silica 100-nm 198 microspheres (Polysciences Inc., Philadelphia, United States) were used to quality check the 199 instrument performance routinely. The particle concentration per method was calculated as 200 the change ( $\Delta$ ) compared to the the control sample, in which PBS replaced the plasma 201 sample.

202

# 203 Protein concentration

204 Protein concentration was determined by bicinchoninic assay (BCA) (Thermo Fischer 205 Scientific, Massachusetts, United States). A standard curve with Bovine Serum Albumin 206 (Thermo Fischer Scientific, Massachusetts, United States) was used to calculate the protein 207 concentration. Isolated EV were diluted 1:2 or 1:6 with RIPA buffer and needle sonicated by 208 a SonoPuls HD2070 (Bandelin, Berlin, Germany) at 40% power for 10 seconds. 25 µL of 209 sonicated sample or standard was incubated in duplicate with 175 µL of a 25:1 ratio between 210 Reagent A and Reagent B (Thermo Fischer Scientific, Massachusetts, United States) and 211 incubated at 37 °C for 30 minutes. After incubation, absorbance was measured at 562 nm 212 using a plate reader (FLUOstar Omega plate reader, BMG Labtech, Aylesbury, United 213 Kingdom).

214

# 215 Transmission Electron Microscopy

Transmission electron microscopy (TEM) of the isolated EV was conducted as previously described [6]. Briefly, grids (300 mesh Cu carbon film) were glow discharged for 20 seconds

9

218 at 15 mA (Leica EM ACE 200). The isolated plasma EV samples were added to the grid for 2 219 minutes, blotted, stained with 2% uranyl acetate for 20 seconds, blotted and allowed to air 220 dry. Images were acquired on a 120 kV Tecnai 12 TEM (Thermo Fischer Scientific, 221 Massachusetts, United States) equipped with a OneView digital camera (Gatan, California, 222 United States). TEM images of control samples, in which the isolation method was run with 223 PBS in the place of the plasma, were obtained for each method. Immunoaffinity-based 224 isolated EV were fixed with 1.6% glutaraldehyde in PBS for 1 hour at 4 °C. Following 225 fixation, the beads were fixed in 4% agarose with PBS. The agarose was cut into small 226 cubes (1-2 mm3). Sections were collected onto 200 mesh Cu grids and imaged using a 227 Gatan OneView camera with a FEI Tecnai 12 TEM at 120kV.

228

# 229 Proteomics

230 Isolated plasma EV were processed for proteomics as previously described [28, 29]. In 231 short, the samples were reduced in 5 mM dithiothreitol for 30 minutes at room temperature. 232 Subsequently, the samples were alkylated with 20 mM iodacetamide for 30 minutes and 233 precipitation using chloroform-methanol precipitation. Quantified protein groups with 22 234 unique peptides were included in the comparison of proteomes. The LFQ values for each 235 protein group was deducted by the LFQ from control samples per isolation method. Protein 236 abundance was normalised by Log-transformation. Gene Ontology (GO) analysis of the 237 protein groups [30] was conducted by using Genontology.org [30] and the data were 238 extracted on 19-07-2021. P-values were corrected for false discovery rate (FDR) and 239 significance was set at p<0.05. Fisher exact tests were conducted using R on published 240 databases EVpedia [31], Vesiclepedia [32] and Exocarta [33].

241

#### 242 EV-Array

Isolated plasma EV were analysed by a targeted EV-Array, which has been described
previously [6, 34]. In short, a protein microarray plate was generated with the following
antibodies: CD146 (P1H12), Flotillin-1, TSG101 (Abnova, Taiwan), CD9, CD81 (Ancell

10

246 corporation, Minnesota, United States); CD16 (3G8, BD Biosciences, California, United 247 States); Alix (3A9), VEGFR2 (7D4-6; Biolegend, California, United States); CD63 (Bio-Rad, 248 California, United States); ICAM-1 (R6.5, eBioscience, California, United States); Endoglin 249 (LSbio, Washington, United States); Tissue factor (323,514), VCAM-1 (HAE-2Z), 250 Thrombomodulin (501733), CD31 (AF806, R&D Systems, Minnesota, United States), VE-251 Cadherin (AF938, R&D Systems, Minnesota, United States). After blocking with the blocking 252 buffer (50 mM ethanolamine, 100 mM Tris, 0.1% SDS, pH 9.0) for 30 minutes, the wells 253 were emptied, and the plate was dried for 5 hours and sealed. The samples were incubated 254 in the antibody coated microarray plate overnight at 2-8 °C. Following a wash, each well was 255 incubated with a 100 µL of a detection antibody cocktail (biotinylated anti-human-CD9, -256 CD63 and -CD81 (Ancell, Minnesota, United States). After another wash, 100 µL 257 streptavidin-Cy3 Life Technologies, Massachusetts, United States) diluted 1:3,000 was 258 added to each well and incubated for 30 minutes. The plate was scanned using a 259 sciREADER FL2 microarray scanner (Scienion AG, Berlin, Germany), at 535 nm and an 260 exposure time of 2,000 milliseconds. For each protein the control, PBS sample value was 261 subtracted from the result.

262

# 263 Western blot

264 Isolated plasma EV or controls were lysed using RIPA buffer with protease and phosphatase 265 inhibitors PhosSTOP (Roche, Basel, Switzerland) and cOmplete (Roche, Basel, Switzerland) 266 and were needle sonicated by a SonoPuls HD2070 (Bandelin, Berlin, Germany) at 40% 267 power for 10 seconds as previously described [5, 6]. Following sonication, samples were 268 incubated at 95 °C for 5 minutes to reduce. 8 µg of protein was combined with NuPage LDS 269 sample buffer (4x) agent (Invitrogen, Massachusetts, United States). The samples were 270 loaded onto a 4-12% bis-tris gradient gel (NuPAGE 4-12% Bis-Tris Protein Gel; 1.5 mm 271 (ThermoFisher Scientific, Massachusetts, United States) with Amersham ECL Full Range 272 ladder (Cytiva Life Sciences, Massachusetts, United States). Separated samples were 273 transferred to a nitrocellulose membrane (Amersham Proton 0.2 µm, GE Healthcare, Illinois,

11

274 United States) and blocked for non-specific binding in 5 % skimmed milk powder (Marvel 275 Original, New York, United States) in 0.5% PBS-tween 20 (Sigma-Aldrich, Missouri, United 276 States) for 1 hour. Membranes were incubated with primary antibodies overnight: ALIX 277 (ab117600, Abcam, Cambridge, United Kingdom) (1/1,000 dilution), CD63 (EXOAB-KIT-1, 278 System Biosciences, California, United States) (1/1,000 dilution), ApoB (Ab139401, Abcam, 279 Cambridge, United Kingdom) (1/20,000 dilution), albumin (MAB1455, R&D Systems, 280 Minneapolis, Canada) (1/8,000 dilution), ApoA-I (Mab36641, R&D systems, Minneapolis, 281 Canada) (1/8,000 dilution) and H3 (D1H2, Cell Signalling Technology, Massachusetts, 282 United States) (1/1,000 dilution) 5 % milk in PBS-tween (PBS-T). Membranes were washed 283 three times with PBS-T and incubated with secondary-horse radish peroxidase (HRP) 284 conjugated antibodies (1/20,000 α-mouse W402B or 1/50,000 α-rabbit W401B, Promega, 285 Wisconsin, United States) for 1 hour. The membranes were washed once again with PBS-T 286 before incubating them with enhance chemiluminescence substrate (Pierce ECL, 287 ThermoFisher Scientific, Massachusetts, United States) for imaging (Bio-Rad ChemiDoc MP 288 Imaging system, California, United States).

289

### 290 Sphingolipidomics

291 Sphingolipids were determined as previously described [35]. 25 µL of each sample were 292 combined with 10 µL solution containing labelled sphingolipid internal standards in LC-MS 293 Methanol (Honeywell, North Carolina, United States) was added to each sample. This was 294 followed by the addition of 100 µL of methanol to each sample. Samples were then vortexed 295 for 30 seconds and sonicated for 15 minutes in a Fisherbrand Ultrasound bath S60 (Fischer-296 Scientific, Massachusetts, United States) with ice. Next, samples were centrifuged at 12,000 297 x g during 15 minutes at 6 $\Box$ C. Finally, 80 µL of the supernatant were transferred to an LC-298 MS amber vial (Waters, Wilmslow, United Kingdom) equipped with a 150 µL insert. Samples 299 were randomized by time point of the individual within an extraction method. Samples were 300 analyzed on an Acquity UPLC coupled to a Xevo TQ-S Mass Spectrometer (Waters, 301 Wilmslow, United Kingdom) as previously described.

# 303 Bioinformatics and Integrated analysis

304 Integrated analysis was conducted by combining data from the NTA, protein concentration, 305 EV-Array, proteomic and sphingolipidomic analysis. The data was normalized per row and 306 log transformed. Following data normalization, a principal component analysis was 307 conducted in R 4.0.0 [37] using the factoextra [38] and FactoMineR [39] packages. For 308 visualization ggplot2 [40] was used. Each of the principal components were then used to 309 create a heatmap by extracting the values from the eigenvalues for each of the principal 310 components and processing them in *pheatmap* [41]. The data was clustered by using double 311 hierarchical clustering using the *pheatmap* R package.

312

# 313 Data availability

All data produced in the present study are available upon reasonable request to the Corresponding Author.

316

# 317 <u>Statistical analysis</u>

318 Data was plotted as mean with standard deviation. Normality of the data was confirmed 319 using QQ plot and D'Agostino-Pearson normality test. For paired analysis, at the two time 320 points, or for two independent groups, paired or unpaired Students T-test were used 321 respectively (GraphPad Prism 9). Correlation analysis was carried out using linear Pearson 322 regression analysis (Graphpad Prism 9). One-way ANOVA with Bonferroni correction post-323 hoc tests were used for analyses with >3 independent groups. The proteomic and lipidomic 324 data was analyzed using a Kruskal-Wallis statistical test with Bonferroni post-hoc tests. p 325 values <0.05 were considered significant.

# 326 **Results**

# 327 Plasma EV number and size is influenced by the isolation method

328 The concentration of isolated EV (expressed as delta over a matched PBS or and IgG control sample) determined by NTA differed per method (UC 9.5 x  $10^9 \pm 1.8 \times 10^9 \text{ EV} / \text{mL}$ . 329 precipitation 6.1 x  $10^{11} \pm 2.7 \times 10^{11}$  EV / mL, acoustic trapping 6.4 x  $10^9 \pm 2.8 \times 10^9$  EV / mL, 330 SEC 5.5 x  $10^9 \pm 1.9$  x  $10^9$  EV / mL and immunoaffinity 2.8 x  $10^{10} \pm 7.1$  x  $10^9$  EV / mL, Figure 331 332 **2A**). In agreement with previously published studies, precipitation yielded significantly higher 333 numbers of particles / mL compared to UC [15, 36] and SEC [15, 37] (both p<0.01). Plasma 334 EV number, isolated by precipitation, were also higher than the concentration acquired by 335 acoustic trapping or by immunoaffinity capture (both p<0.01) (Figure 2A). The size and 336 concentration distribution for each biological replicate exhibited uniformity within each 337 isolation method and the different isolation methods did give a similar size distribution profile 338 overall, which ranged from 15 nm (Figure 2B). However, the mean size of EV isolated by 339 UC was significantly higher compared to the other methods (UC 143.7  $\pm$  3.4 nm, versus 340 precipitation 94.2 ± 3.9 nm, acoustic trapping 81.2 ± 3.9 and SEC 87.2 ± 1.5, p<0.01 all) 341 (Table 1).

342

# 343 Plasma EV protein concentration

344 The protein concentration (expressed as the change over a matched PBS or and IgG 345 control) also differed across the EV isolation methods: UC 982  $\pm$  113  $\mu$ g / mL, precipitation 9,478  $\pm$  3,174  $\mu$ g / mL, acoustic trapping 1,211  $\pm$  141  $\mu$ g / mL, SEC 382  $\pm$  51  $\mu$ g / mL and 346 347 immunoaffinity 33 ± 12 µg / mL (Figure 2C). EV generated by precipitation had a 348 significantly higher protein concentration compared to UC, acoustic trapping, SEC or 349 immunoaffinity (all p<0.01, Figure 2C). The purity of EV isolation can be estimated by 350 calculating a ratio of EV number (EV / mL) to protein concentration (µg / mL) [44]. The EV purity ratio differed between isolation method: UC 9.0 x  $10^6 \pm 1.4 \times 10^6$ ; precipitation 4.7 x 351  $10^8 \pm 1.5 \times 10^8$ ; acoustic trapping 2.1 x  $10^7 \pm 7.6 \times 10^6$ ; SEC 6.8 x  $10^6 \pm 4.0 \times 10^6$  and 352 immunoaffinity capture 3.1 x  $10^8 \pm 1.0 \times 10^8$ . Both the immunoaffinity and precipitation 353

14

354 methods achieved a significantly higher EV purity ratio when compared to UC, SEC or 355 acoustic trapping (p<0.01 compared to all methods) (**Supplemental Figure 1**).

356

### 357 Plasma EV protein characterisation by Western blot

358 As NTA is unable to distinguish between plasma EV and similarly sized protein aggregates 359 and lipoproteins, we analysed the isolated plasma EV obtained from each method for a 360 number of markers by western blotting. ALIX and CD63 were included as the EV markers. 361 For the plasma lipoprotein contaminants, we measured ApoB and ApoA-I. Histone H3 for 362 cellular contaminant by western blot and albumin was also included in the set. Each isolation 363 method showed the presence of EV markers ALIX and CD63 (Figure 2D). Apolipoproteins 364 (ApoA-I and ApoB) were also present in all isolation methods. All methods were negative for 365 markers of cellular contamination by histone H3. Surprisingly, the IgG isotype control for 366 immunoaffinity capture using CD9, CD63 and CD81 also showed the presence of EV 367 markers ALIX, CD63 and ApoB, albumin, ApoA-I but histone H3 was absent (Figure 2D).

368

### 369 Plasma EV morphology by TEM

370 To determine the morphology of isolated plasma EV, we undertook TEM for the five different 371 plasma EV isolation methods versus a matched PBS control or an IgG control for 372 immunoaffinity capture beads. TEM analysis showed EV-like particles for each isolation 373 method and an absence of EV-like particles in their respective PBS isolation controls 374 (Figure 2E-H). Immunoaffinity beads CD9, CD63 and CD81 were embedded in agar and 375 sectioned to visualise the bead surface for EV-like structures versus the IgG control. IgG 376 control showed no EV-like particles present (Figure 2I). Immunoaffinity capture using CD9, 377 CD63 and CD81 beads showed intact EV-like particles captured on the bead surface 378 (Figure 2J).

379

### 380 Plasma EV compositional analysis using a high throughput protein EV-Array

15

381 The results detailed above provide evidence for the relative success of each method to yield 382 plasma EV and assessment of relative plasma EV purity [39]. However, these techniques do 383 not readily distinguish the abundance of specific plasma EV populations carrying, for 384 instance, specific cell-associated markers, or easily allow quantitative assessment of the 385 abundance of contaminating lipoproteins. Thus, we probed the composition of the plasma 386 EV isolated from each method for general EV markers CD9, CD63, CD81, ALIX, TSG101, 387 Flotillin 1, Annexin V and a panel of 18 cell associated markers, which may distinguishes EV 388 from platelets, endothelial cells, immune cells, muscle and lipoprotein contaminants 389 apolipoprotein E (ApoE) and apolipoprotein H (ApoH) using a validated high throughput EV-390 protein antibody array (Figure 3) [34]. We utilised a matched PBS control for UC, 391 precipitation, acoustic trapping and SEC and an IgG control for immunoaffinity capture. For 392 the EV-associated proteins, CD9 and CD81, they were significantly higher in plasma EV 393 isolated by UC compared to the other methods (p<0.01 for both). Annexin V was significantly 394 higher in the acoustic trapping samples compared to SEC and immunoaffinity capture 395 (p<0.01 and p<0.05, respectively).

396

397 Hierarchical clustering of the EV-Array acquired data for the different isolation methods 398 indicates that there are significant method-dependent differences for cell associated EV 399 markers (Figure 3). CD31 was significantly higher in precipitation isolated plasma EV versus 400 acoustic trapping (p<0.05). CD41 was significantly higher in UC isolated plasma EV 401 compared to precipitation isolated EV (p<0.05) and CD16 content was significantly higher in 402 the precipitation isolated plasma EV samples compared to SEC (p<0.01). There were no 403 differences between immunoaffinity capture using CD9, CD63 and CD81 and IgG controls 404 (Figure 3).

405

406

407 Unbiased proteomic analysis of plasma EV

16

408 We next determined the proteomic profile of each isolation method using unbiased LC-409 MS/MS versus their respective PBS or IgG controls for each method. The proteomic profile 410 following plasma EV isolation showed a significantly higher number of quantified protein 411 groups compared to their respective controls for all isolation methods, except immunoaffinity 412 capture, which displayed similar results to the IgG control beads (UC p<0.01, precipitation 413 p<0.05, acoustic trapping p<0.01 and SEC p<0.01, Figure 4A). The choice of plasma EV 414 isolation method influenced the overall EV-proteome, but nine protein groups were common 415 across all methods (Supplemental Figure 2). These were: immunoglobulin heavy constant 416 gamma 1, alpha-2-macroglobulin, haptoglobin, immunoglobulin heavy constant µ, 417 immunoglobulin kappa constant, serpin family A member 1, albumin, fibrinogen alpha chain 418 and Apo-A1.

419

420 We used hierarchical clustering of the top 30 quantified protein groups across the different 421 plasma EV isolation methods and found a distinct separation between isolation methods. UC 422 and SEC isolated plasma EV clustered together and precipitation, acoustic trapping and 423 immunoaffinity capture formed a distinct separate cluster (Figure 4B). Hierarchical clustering 424 indicates that these differences between UC/SEC and precipitation, acoustic trapping and 425 immunoaffinity capture were driven by an abundance of protein groups with common plasma 426 proteins (ALB, A2M, ApoB, C3, TF, HP, Apo-A1, SERPINA1, CP and ITIH2), fibrinogens 427 (FGG and FGB) and immunoglobulins (IGHG1, IGKC, IGHG3, IGHM, IGK, IGHG2).

428

To better understand the nature of the proteomic profile for each isolation method, we conducted unbiased Gene Ontology (GO) pathway analysis of the protein groups associated with each isolation method. All methods showed a significant association with EV pathways: Blood Microparticle GO: 0072562 and Extracellular Exosome GO:0070062 (all p<0.01, **Supplemental Figure 3A**). However, there was no clear separation between the different isolation methods using this pathway analysis approach. To further scrutinize the EV proteomic profile obtained per plasma EV isolation method we undertook a statistical

17

436 comparison using a Fisher's exact test with published EV-databases EVpedia [31], 437 Vesiclepedia [32] and Exocarta [33]. This determined the similarity between plasma EV 438 proteomic profiles obtained from the five different isolations methods to those published 439 previously by showing the size of the intersect. There was a significant overlap between the 440 five different isolation methods and the archived EV databases (p<0.05, all methods, 441 Supplemental Figure 3B). UC, SEC and immunoaffinity capture showed the greatest 442 similarity with published databases. Whereas precipitation and acoustic trapping showed 443 less similarity. Furthermore, we determined whether our plasma EV acquired proteomic 444 profiles from the five different methods were similar to previously published plasma EV 445 proteomic data for Exospin, SEC, ExoQuick, IZON35, IZON70, Optiprep and Exo-easy [16, 446 17] and found a significant overlap for all five plasma EV isolation methods (p<0.01) 447 (Supplemental Figure 4).

448

#### 449 <u>Targeted sphingolipidomic of plasma EV</u>

450 EV membranes are largely composed of lipids [46] and lipoproteins are a predominant 451 contaminant in plasma EV samples [41], which are influenced by the choice of isolation 452 method [12, 42]. We compared the lipidomic profile of the different plasma EV isolations 453 methods by undertaking targeted sphingolipidomic analysis. The sphingolipidomic analysis 454 showed a significantly higher number of sphingolipids compared to the respective controls 455 for all isolation methods except immunoaffinity capture (UC p<0.01, precipitation p<0.05, 456 acoustic trapping p<0.01 and SEC p<0.01, Figure 5A). However, there were distinct 457 sphingolipidomic differences between the other methods. Eleven of the quantified 458 sphingolipids were common to all methods, which were DhCer(d18:0/24:0), Cer(d18:1/22:0), 459 Cer(d18:1/24:1), Cer(d18:1/24\_:0), SM(d18:1/16:0), SM(d18:1/18:0), SM(d18:1/24:1), 460 SM(d18:1/24:0), HexCer(d18:1/16:0), HexCer(d18:1/24:1) and LacCer(d18:1/24:1) 461 (Supplemental Figure 5). Hierarchical clustering analysis of the sphingolipidomic profile for 462 each of the isolation methods showed that there are three distinct clusters (Figure 5B). 463 Immunoaffinity capture and precipitation formed two separate individual clusters, whilst UC,

18

464 acoustic trapping and SEC clustered together. Hierarchical clustering indicates that these 465 group differences were driven by an abundance of sphingomyelins (16:0, 18:0, 24:0 and 466 24:1), ceramides (22:0, 24:0 and 24:1), hexosylceramides (24:1) and lactosylceramides 467 (16:0) in the precipitation group and a lack of these sphingolipids in the immunoaffinity 468 capture group.

469

# 470 Integrated comparison of plasma EV isolation methods

471 These data shows that plasma EV isolation methods have divergent impact on the yield of 472 EV, their purity, the type of EV isolated from plasma that are associated with a particular cell 473 source and the overall proteomic and sphingolipidomic profile. To better understand how 474 these individual method associated differences influenced the plasma profile, we undertook 475 integrated analysis of all the different plasma EV isolation methods with all of the acquired 476 data. This included the EV particle concentration, protein concentration, EV-protein array 477 data, proteomic and sphingolipidomic data. To condense the multiple different variables, we 478 converted the data into principal components. Principal component analysis with two 479 components (PCA1 and PCA2) accounted for 47.2% of the variance and showed clear 480 separation between the different isolation methods (Figure 6A/B). UC, SEC and 481 precipitation form distinct clusters, whereas acoustic trapping and immunoaffinity capture 482 clustered together. Specific principal component analysis indicated that the PCA1 is driven 483 by proteomics acquired data and PCA2 is driven by sphingolipidomic data (Supplementary 484 Figure 6). These integrated data show that the EV isolation method influences the omic and 485 integrated-based plasma EV-profile, which may influence interpretation of EV-acquired data 486 for clinical biomarker discovery and precision diagnostics.

487

# Plasma EV isolation methods influence the diagnostic potential of plasma EV from patients following MI

We next determined whether the choice of plasma EV isolation method impacts the ability to
 detect changes in EV-profile in a disease state. We obtained plasma at time of presentation

19

with MI, but prior to percutaneous coronary intervention (PCI), and a matched control plasma
sample was obtained at 1-month post-MI from the same patients. The clinical patient
characteristics are detailed in **Table 2**.

- 495
- 496
- 497

# 498 Plasma EV concentration in MI is influenced by the isolation method

499 To mitigate any potential variability in bio-banked plasma samples we used three technical 500 plasma replicates per patient, per time point and per method. There were significantly more 501 plasma EV at time of presentation with MI versus the 1 month control follow up when plasma 502 EV were isolated by UC, precipitation and acoustic trapping (p<0.05 for all) (Figure 7A), but not by SEC and immunoaffinity capture (UC presentation: 2.8 x 10<sup>9</sup> EV / mL vs. UC follow-503 up: 2.1 x 10<sup>9</sup> EV / mL; precipitation presentation: 1.5 x 10<sup>12</sup> EV / mL vs. precipitation follow-504 up: 7.9 x  $10^{11}$  EV / mL; acoustic trapping presentation: 4.3 x  $10^{10}$  EV / mL vs. acoustic 505 trapping follow-up: 1.9 x 10<sup>10</sup> EV / mL; SEC presentation: 2.5 x 10<sup>11</sup> EV / mL vs. SEC follow-506 up: 9.2 x  $10^{10}$  EV / mL and immunoaffinity presentation: 2.0 x  $10^{11}$  EV / mL vs. 507 immunoaffinity capture follow-up: 9.8 x 10<sup>10</sup> EV / mL, Figure 7A). The technical variance 508 509 between the three independent isolations from each patient, and at each time, point showed 510 that SEC gave significantly less variance compared to UC ( $10.0 \pm 3.1$  % vs.  $22.7 \pm 13.0$  %, 511 p<0.01) (Supplemental Figure 7A). The mean plasma EV size was similar between the 512 time of presentation and 1 month follow up control for the five different plasma EV isolation 513 methods (Supplemental Figure 7B) and the size and concentration distribution profile 514 showed no distinct differences between time points or dependent on the plasma EV isolation 515 method (Supplemental Figure 7C).

516

517 <u>The plasma EV isolation method influences plasma EV concentration association with infarct</u>
 518 <u>size</u>

20

519 We have previously reported that the total concentration of plasma EV in the peripheral 520 blood isolated by UC at the time of presentation correlates with the size of myocardial injury 521 and scar, determined by late gadolinium enhanced (LGE) MRI 6 months post-MI [5, 6]. 522 Therefore, we determined whether plasma EV concentrations from the five different plasma 523 EV isolation methods influenced the ability to determine this important clinical association. 524 Infarct size at 6-months post-MI significantly correlated with the plasma EV concentration at time of presentation for UC samples ( $R^2 = 0.89$ , p=0.02), but not for precipitation, acoustic 525 trapping, SEC or immunoaffinity capture ( $R^2$ =0.10 p=0.60,  $R^2$ =0.16 p=0.50,  $R^2$ =0.05 p=0.71 526 527 and  $R^2$ =0.10, p=0.78, respectively) (Figure 7B).

528

# 529 <u>Cell associated plasma EV are not influenced by the isolation method in MI</u>

530 We determined whether the isolation methods influenced cell associated plasma EV-531 markers in MI patients at presentation versus the respective 1 month follow up sample. The 532 high through put EV-Array data was expressed as fold change over the matched follow-up 533 control samples per patient. Plasma EV markers were increased at time of presentation vs. 534 follow-up control (Figure 7C). However, the pattern of change in plasma EV-markers were 535 not consistent across the different isolation methods (Figure 7C). Hierarchical clustering of 536 the plasma EV marker response at the time of presentation with MI showed method-537 dependent clustering. Similarly, cell associated markers on plasma EV were differentially 538 enriched following MI (Figure 7C). Once again, unbiased clustering showed method-539 dependent groupings. Together these data suggest that changes in plasma-EV protein are 540 influenced by the choice of plasma EV isolation method following MI in isolation and when 541 clustered together.

542

543 <u>Plasma EV sphingolipidomic profiles are altered following MI and influenced by the isolation</u>
 544 <u>method</u>

Next, we profiled EV-sphingolipids in the acute phase following MI (calculated as fold over
matched follow-up control samples) using the different plasma EV isolation methods. Plasma

21

547 EV-sphingolipidomic profiles for samples generated by precipitation, acoustic trapping and 548 SEC contained significantly more quantified lipid groups at time of presentation with MI 549 versus samples obtained by UC and immunoaffinity capture (p<0.01, all). We ranked plasma 550 EV-lipid profiles based on their overall abundance of lipid groups and found that ceramides 551 were significantly higher in the precipitation isolated plasma EV samples, followed by SEC, 552 acoustic trapping, ultracentrifugation / immunoaffinity capture (p<0.01). Whereas the 553 sphingomyelins were significantly higher in the precipitation group versus all other isolation 554 methods (p<0.001) (Figure 7D). The clustered plasma EV-sphingolipid profile following MI 555 was influenced by the choice of isolation method. Several ceramides and sphingomyelins 556 were significantly higher in the plasma EV isolated by precipitation or acoustic trapping 557 compared to UC (Supplemental Figure 8). In addition, the fold increase of Cer(d18:1/22:0), 558 SM(d18:1/18:1) and sphinganine (d18:0) in plasma EV isolated by precipitation at time of 559 presentation vs. 1-month follow up significantly correlated with the infarct size of the patients at 6-months post-MI ( $R^2 = 0.91 p=0.01$ ,  $R^2 = 0.78 p=0.05$  and  $R^2 = 0.78 p=0.05$ , respectively) 560 561 (Supplemental Figure 9). This result further confirmed that plasma EV isolation methods, 562 using targeted sphingolipidomic methods, are associated with unique method dependent 563 profiles in patients following MI.

564

#### 565 Integrated-omics comparison of plasma EV isolation methods in MI patients

566 Finally, we integrated all the acquired plasma EV data from the MI patients in the acute 567 presentation and follow-up time points. A principal component analysis was constructed to 568 assess if the plasma EV profile at time of presentation differed from follow-up using a 95% 569 confidence level. Integrated analysis showed that plasma EV profiles were only 570 distinguishable at time of presentation with MI for precipitation and acoustic trapping, but not 571 for those plasma EV isolated by UC, SEC and immunoaffinity capture (Figure 8). These 572 findings indicate that different plasma EV isolation methods influence the diagnostic potential 573 of plasma liberated EV following MI when multiple datasets are integrated to determine 574 plasma EV profiles for potential panel biomarker discovery.

# 575 Discussion

576 Plasma EV-cargo may provide unparalleled insight into tissue homeostasis and pathological 577 processes to facilitate identification of patients for focused therapies, but the methods to 578 isolate plasma EV may impact the EV characteristics. Here, we found that; (I) the choice of 579 plasma EV isolation method affected the plasma EV concentration, sphingolipid and 580 proteomic profile, (II) but the five different plasma EV isolation methods shared a common 581 EV protein and sphingolipid profile. (III) Plasma EV isolation by immunoaffinity capture using 582 anti-CD9, -CD63 and -CD81 coated antibody beads with the current protocol yields a similar 583 profile to IgG control beads. (IV) The isolation method affected the ability to detect 584 alterations in plasma EV sphingolipids and proteins in MI patients and (V) their association 585 with infarct size determined by cardiac MRI 6 months post-MI. For example, the plasma EV 586 concentration at time of presentation obtained using UC provides prognostic information, but 587 this method is less suitable as a tool to generate EV with higher purity for use in mechanistic 588 studies.

589

590 Previous studies have sought to determine the influence of plasma EV isolation methods, 591 but have often focused on comparing the net influence on the EV-proteome [3, 16, 17, 43] or 592 RNA profiles [16] after isolation. These approaches can neglect the increased dimensionality 593 of EV components, which carry numerous biologically active molecules such as proteins, 594 lipids, RNA/DNA and metabolites. Furthermore, there is varied assessment of 595 contaminations in EV preparations for use in 'omics' studies, which may mask or skew the 596 interpretation of datasets. The approach employed here utilizes the same independent 597 biological replicates across multiple methods for plasma EV isolation and characterization, in 598 conjunction with a control PBS/vehicle sample or an IgG for immunoaffinity capture beads. 599 Here, the repeated analysis of the same plasma samples across multiple methods has 600 enabled individual biological variability and potential plasma EV isolation irregularities to be 601 explored. By using individual and integrated analysis, we showed that each method of 602 plasma EV isolation was internally consistent; in so much that the samples clustered

23

according to their isolation method in unsupervised hierarchical clustering and principal
 component analysis of all the acquired data.

605

606 Consistent with previous reports, our plasma EV-proteome was dependent on the plasma 607 EV isolation method [16, 17]. However, our data shows that there are common plasma 608 proteins, such as albumin and apolipoproteins ApoA-I and ApoB, present in all five isolation 609 methods tested, with significant similarities to archived EV-databases [31-33] and published 610 studies [16, 17, 31]. In particular, the plasma EV-proteome indicated that UC/SEC cluster 611 together based on the top 30 protein groups quantified, due to higher quantities of 612 fibrinogens and immunoglobulins compared to the other methods. This is, potentially, a 613 methodological constraint of employing untargeted mass spectrometry on plasma EV, which 614 favors the most abundant peptides.

615

616 To better determine the protein profile of known plasma EV markers and cell associated 617 markers, we utilized a high throughput EV-Array [50] following plasma EV isolation from the 618 five different methods. We found that CD9 and CD81 were the most abundant in plasma EV 619 derived by UC versus precipitation and SEC in healthy volunteers. Additionally, we found 620 that cell-associated markers such as CD41 (platelets) and CD16 (immune cells) were 621 enriched in UC and precipitation compared to other methods only in healthy volunteers. This 622 high throughput antibody EV-Array circumvents issues of non-EV associated protein and 623 lipid contaminants in plasma EV preparations. However, the five different plasma EV 624 isolation methods used here may have influenced the EV-protein corona. Proteins such as 625 albumin and apolipoproteins (ApoA-I, ApoB, ApoC-III and ApoE) show an association with 626 the surface of EV [45], which may influence antibody mediated binding to the array or 627 subsequent detection of EV-associated proteins in this sandwich ELISA like technique. 628 Protein coronas found on EV are affected by the isolation method [45] and our data shows 629 that the plasma EV-proteome and EV-Array acquired data are also influenced by the 630 isolation method. Indeed, our western blot and proteomic data reported considerable

24

variation in the amount of albumin across the methods, which is a predominant protein in the EV protein corona. In particular, precipitation isolated preparations was associated with lower albumin, which could be due to the presence of PEG and high salt concentrations in the isolation buffer that might be expected to influence albumin associations with the EV protein corona. The temporal dynamics of the EV-protein and possibly EV-lipid corona are poorly understood, and further elucidation of these interactions will be essential to understand the data from these preparations.

638

639 Immunoaffinity based methods, such as magnetic and polystyrene bead conjugations to 640 specific antibodies, such as tetraspanins (CD9, CD63 and CD81), have been heralded as an 641 important advancement in the capture of highly pure EV populations from the plasma. 642 Immunoaffinity based methods could circumvent issues of lipoprotein and protein 643 contamination in plasma EV yields, which are common in methods that use EV physical 644 characteristics such as size and density for isolation such as UC and SEC [16, 46]. To the 645 best of our knowledge this is the first study to compare magnetic beads coated with 646 antibodies for tetraspanins (CD9, CD63 and CD81) with a matched IgG control for plasma 647 EV isolation, using detailed integrated analyses. The plasma EV-profile of proteins and lipids 648 for the immunoaffinity beads and matched IgG control was similar by Western blot, EV-649 protein-array, the number of peptides groups in proteomic profiles, GO pathway analysis and 650 targeted sphingolipidomics. TEM imaging of IgG beads showed no visible EV-like particles 651 or membranous structures, indicative of whole or sheared EV-particles, captured to the bead 652 surface. However, we hypothesize that soluble non-EV-associated proteins (such as C3, 653 A2M, ALB and fibrinogens A and B) and lipids (such as ApoB, ApoE and ApoA-I) are 654 interacting with IgG beads, which have become associated with EV-profiles in omics studies 655 and in archived databases [31-33]. Studies using less complicated matrices, like conditioned 656 cell culture media, show a more robust distinction between anti-CD9, CD63 and CD81 beads 657 versus IgG control beads [8, 47], indicating that the similarity between tetraspanin and IgG 658 antibody beads here might be matrix specific. Future plasma EV studies using antibody-

25

659 bead isolation should include a matched IgG control per characterisation when using omic-

660 approaches

661

662 Having determined plasma EV isolations method similarities and differences on the EV-663 characteristics and cargo in healthy volunteers, we assessed the influence of plasma EV 664 isolation methods in a clinical situation where plasma EV number and composition are 665 altered. We have previously shown that plasma EV are altered following MI to mediate long 666 range signalling and induce the mobilization of splenic-neutrophils, splenic-monocytes and 667 orchestrate their transcriptional programming [5, 6]. The choice of plasma EV isolation 668 method determined whether there was a higher concentration of EV immediately following 669 MI compared to a 1-month follow-up control sample from the same patients. The new data 670 here support our previous observations that the concentration of plasma EV isolated by UC 671 from the time of presentation with MI correlates with the infarct size [5]. However, plasma EV 672 concentrations derived from the other isolation methods in the same patients did not 673 associate with infarct size. One possible explanation is the modest sample size utilised in 674 this multi-method comparison (N=6), which is smaller than those utilised by us in previous 675 publications (N=15-22) [5, 6].

676

677 Plasma EV sphingolipids are predictive of MI [3]. However, the influence of plasma EV 678 isolation methods on the plasma EV-sphingolipidomic profile were not reported. We found a 679 distinct sphingolipid profile between the plasma EV isolation methods. Precipitation-based 680 EV isolation yields a significantly higher lipid content, principally due to higher proportions of 681 sphingomyelins and ceramides. Sphingomyelins are found in cell membranes and 682 associated with high- and low-density lipoproteins [48, 49]. The high presence of 683 sphingomyelins and ceramide in the plasma EV profile of the precipitation-based method is 684 likely due to the co-isolation of lipoproteins. PEG-based solutions co-isolate lipoproteins [56]. 685 Lipoproteins contain ApoA-I and ApoB, which were higher in plasma EV derived by 686 precipitation-based isolation when compared to the other methods by Western blot.

26

687 Lipoproteins can also masquerade as EV-like particles in dynamic light scattering in 688 techniques such as NTA [12]. Precipitation isolated plasma EV had the highest 689 concentration of particles / mL when compared to other methods. EV Cer(d18:1/20:0) only 690 showed elevation in precipitation-based isolation compared other methods. Similarly, 691 precipitation isolated EV showed sphinganine(d18:0) correlated with infarct size at 6-months, 692 but this was not the case for the other methods. Analysis of plasma EV-sphingolipid remains 693 challenging due to constraints due to lipoparticle remnants [57]; however we show here for 694 the first time there are common sphingolipids for different plasma EV isolation methods. In 695 particular, plasma EV-protein and EV-sphingolipids clustered uniquely based on the isolation 696 method, which may impact plasma EV diagnostics where a panel of proteins and 697 sphingolipids are used for differentiation of clinical disease or outcome.

698

699 In summary, our data show that the choice of plasma EV isolation method influences the 700 concentration of plasma EV, the EV-proteome and EV-sphingolipid profile in healthy 701 volunteers and MI patients, where methodological differences determined associations with 702 infarct size. Precipitation based plasma EV isolation gives the highest particle concentration 703 and enriches for more sphingolipids, but co-isolate large quantities of apolipoproteins. In 704 addition, immunoaffinity capture by using antibodies against tetraspanins yields similar EV-705 protein and EV-sphingolipid profiles to IgG control beads. Unbiased integrated analysis 706 shows that plasma EV isolation methods cluster independently, but despite the selection 707 predispositions imposed by each method, a core of EV associated proteins and lipids was 708 detectable using all the approaches.

# 709 Acknowledgments

710 DP acknowledges his funding from the Department of Pharmacology, the Alison Brading 711 Memorial Fund Lady Margaret Hall, the Clarendon Fund provided by the University of Oxford 712 and the Medical Research Council (MR/N013468/1). NA and RC acknowledge support by 713 research grants from the British Heart Foundation (BHF) Centre of Research Excellence, 714 Oxford (NA and RC: RE/13/1/30181 and RE/18/3/34214); British Heart Foundation Project 715 Grant (NA and RC: PG/18/53/33895); the Tripartite Immunometabolism Consortium, Novo 716 Nordisk Foundation (RC: NNF15CC0018486); Oxford Biomedical Research Centre (BRC); 717 Nuffield Benefaction for Medicine and the Wellcome Institutional Strategic Support Fund 718 (ISSF) (NA) and a Health Research Bridging Salary Scheme (HRBSS) to N.A. BZ work was 719 supported by funding from the European Union's Horizon 2020 Research and Innovation 720 Program under Marie Sklodowska-Curie Grant Agreement 812890, ArthritisHeal. The views 721 expressed are those of the author(s) and not necessarily those of the National Health 722 Service, the National Institutes of Health Research or the Department of Health

723

#### 724 **Declaration statement**

The Author(s) declare(s) that there is no conflict of interest.

28

# 726 References

de Miguel Pérez, D., et al., Extracellular vesicle-miRNAs as liquid biopsy biomarkers
 for disease identification and prognosis in metastatic colorectal cancer patients. Sci Rep,
 2020. 10(1): p. 3974.

2. Dong, L., et al., Circulating Long RNAs in Serum Extracellular Vesicles: Their

731 Characterization and Potential Application as Biomarkers for Diagnosis of Colorectal Cancer.

732 Cancer Epidemiol Biomarkers Prev, 2016. 25(7): p. 1158-66.

Burrello, J., et al., Sphingolipid composition of circulating extracellular vesicles after
myocardial ischemia. Sci Rep, 2020. 10(1): p. 16182.

Kalani, M.Y.S., et al., Extracellular microRNAs in blood differentiate between
ischaemic and haemorrhagic stroke subtypes. J Extracell Vesicles, 2020. 9(1): p. 1713540.

737 5. Akbar, N., et al., Endothelium-derived extracellular vesicles promote splenic
 738 monocyte mobilization in myocardial infarction. JCI Insight, 2017. 2(17).

Akbar, N., et al., Rapid neutrophil mobilisation by VCAM-1+ endothelial extracellular
vesicles. Cardiovasc Res, 2022.

741 7. Evander, M., et al., Non-contact acoustic capture of microparticles from small plasma
742 volumes. Lab Chip, 2015. 15(12): p. 2588-96.

Kowal, J., et al., Proteomic comparison defines novel markers to characterize
heterogeneous populations of extracellular vesicle subtypes. Proc Natl Acad Sci U S A,
2016. 113(8): p. E968-77.

Onódi, Z., et al., Isolation of High-Purity Extracellular Vesicles by the Combination of
 Iodixanol Density Gradient Ultracentrifugation and Bind-Elute Chromatography From Blood
 Plasma. Front Physiol, 2018. 9: p. 1479.

10. Nordin, J.Z., et al., Ultrafiltration with size-exclusion liquid chromatography for high

yield isolation of extracellular vesicles preserving intact biophysical and functional properties.

751 Nanomedicine, 2015. 11(4): p. 879-83.

Geyer, P.E., et al., Plasma Proteome Profiling to detect and avoid sample-related
biases in biomarker studies. EMBO Mol Med, 2019. 11(11): p. e10427.

29

Brennan, K., et al., A comparison of methods for the isolation and separation of
extracellular vesicles from protein and lipid particles in human serum. Scientific Reports,
2020. 10(1): p. 1039.

Van Deun, J., et al., The impact of disparate isolation methods for extracellular
 vesicles on downstream RNA profiling. J Extracell Vesicles, 2014. 3.

759 14. Thery, C., et al., Minimal information for studies of extracellular vesicles 2018

760 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and

vpdate of the MISEV2014 guidelines. J Extracell Vesicles, 2018. 7(1): p. 1535750.

Tian, Y., et al., Quality and efficiency assessment of six extracellular vesicle isolation

methods by nano-flow cytometry. J Extracell Vesicles, 2020. 9(1): p. 1697028.

Veerman, R.E., et al., Molecular evaluation of five different isolation methods for
extracellular vesicles reveals different clinical applicability and subcellular origin. Journal of
Extracellular Vesicles, 2021. 10(9): p. e12128.

de Menezes-Neto, A., et al., Size-exclusion chromatography as a stand-alone
methodology identifies novel markers in mass spectrometry analyses of plasma-derived
vesicles from healthy individuals. J Extracell Vesicles, 2015. 4: p. 27378.

Gidlöf, O., et al., Proteomic profiling of extracellular vesicles reveals additional
diagnostic biomarkers for myocardial infarction compared to plasma alone. Sci Rep, 2019.
9(1): p. 8991.

19. Askeland, A., et al., Mass-Spectrometry Based Proteome Comparison of
Extracellular Vesicle Isolation Methods: Comparison of ME-kit, Size-Exclusion
Chromatography, and High-Speed Centrifugation. Biomedicines, 2020. 8(8): p. 246.

Palviainen, M., et al., Extracellular vesicles from human plasma and serum are
carriers of extravesicular cargo-Implications for biomarker discovery. PLoS One, 2020.
15(8): p. e0236439.

Cao, F., et al., Proteomics comparison of exosomes from serum and plasma
between ultracentrifugation and polymer-based precipitation kit methods. Electrophoresis,
2019. 40(23-24): p. 3092-3098.

30

Jung, H.H., et al., Cytokine profiling in serum-derived exosomes isolated by different
methods. Scientific Reports, 2020. 10(1): p. 14069.

Stranska, R., et al., Comparison of membrane affinity-based method with sizeexclusion chromatography for isolation of exosome-like vesicles from human plasma.
Journal of Translational Medicine, 2018. 16(1): p. 1.

787 24. Gutiérrez García, G., et al., Analysis of RNA yield in extracellular vesicles isolated by

membrane affinity column and differential ultracentrifugation. PLoS One, 2020. 15(11): p.
e0238545.

Peterka, O., et al., Lipidomic characterization of exosomes isolated from human
plasma using various mass spectrometry techniques. Biochim Biophys Acta Mol Cell Biol
Lipids, 2020. 1865(5): p. 158634.

793 26. Shtam, T., et al., Evaluation of immune and chemical precipitation methods for
794 plasma exosome isolation. PLoS One, 2020. 15(11): p. e0242732.

795 27. Welton, J.L., et al., Ready-made chromatography columns for extracellular vesicle
796 isolation from plasma. J Extracell Vesicles, 2015. 4: p. 27269.

797 28. Thompson, A.G., et al., CSF extracellular vesicle proteomics demonstrates altered
798 protein homeostasis in amyotrophic lateral sclerosis. Clin Proteomics, 2020. 17: p. 31.

Subedi, P., et al., Comparison of methods to isolate proteins from extracellular
vesicles for mass spectrometry-based proteomic analyses. Anal Biochem, 2019. 584: p.
113390.

30. Mi, H., et al., PANTHER version 14: more genomes, a new PANTHER GO-slim and
improvements in enrichment analysis tools. Nucleic Acids Res, 2019. 47(D1): p. D419-D426.

804 31. Kim, D.K., et al., EVpedia: an integrated database of high-throughput data for
805 systemic analyses of extracellular vesicles. J Extracell Vesicles, 2013. 2.

806 32. Kalra, H., et al., Vesiclepedia: a compendium for extracellular vesicles with
807 continuous community annotation. PLoS Biol, 2012. 10(12): p. e1001450.

33. Simpson, R.J., H. Kalra, and S. Mathivanan, ExoCarta as a resource for exosomal
research. J Extracell Vesicles, 2012. 1.

810	34.	Jorgensen, M., et al., Extracellular Vesicle (EV) Array: microarray capturing of
811	exoso	mes and other extracellular vesicles for multiplexed phenotyping. J Extracell Vesicles,
812	2013.	2.
813	35.	Akawi, N., et al., Fat-Secreted Ceramides Regulate Vascular Redox State and
814	Influer	nce Outcomes in Patients With Cardiovascular Disease. Journal of the American
815	Colleg	e of Cardiology, 2021. 77(20): p. 2494-2513.
816	36.	Serrano-Pertierra, E., et al., Characterization of Plasma-Derived Extracellular
817	Vesicl	es Isolated by Different Methods: A Comparison Study. Bioengineering (Basel), 2019.
818	6(1).	
819	37.	Gámez-Valero, A., et al., Size-Exclusion Chromatography-based isolation minimally
820	alters	Extracellular Vesicles' characteristics compared to precipitating agents. Sci Rep, 2016.
821	6: p. 3	3641.
822	38.	Webber, J. and A. Clayton, How pure are your vesicles? J Extracell Vesicles, 2013.
823	2.	
824	39.	Théry, C., et al., Minimal information for studies of extracellular vesicles 2018
825	(MISE	V2018): a position statement of the International Society for Extracellular Vesicles and
826	update	e of the MISEV2014 guidelines. J Extracell Vesicles, 2018. 7(1): p. 1535750.
827	40.	Skotland, T., et al., An emerging focus on lipids in extracellular vesicles. Adv Drug
828	Deliv F	Rev, 2020. 159: p. 308-321.
829	41.	Karimi, N., et al., Detailed analysis of the plasma extracellular vesicle proteome after
830	separa	ation from lipoproteins. Cell Mol Life Sci, 2018. 75(15): p. 2873-2886.
831	42.	Yuana, Y., et al., Co-isolation of extracellular vesicles and high-density lipoproteins
832	using	density gradient ultracentrifugation. J Extracell Vesicles, 2014. 3.
833	43.	Gidlof, O., et al., Proteomic profiling of extracellular vesicles reveals additional
834	diagno	ostic biomarkers for myocardial infarction compared to plasma alone. Sci Rep, 2019.

835 9(1): p. 8991.

44. Bæk, R. and M.M. Jørgensen, Multiplexed Phenotyping of Small Extracellular
Vesicles Using Protein Microarray (EV Array). Methods Mol Biol, 2017. 1545: p. 117-127.

32

45. Tóth, E., et al., Formation of a protein corona on the surface of extracellular vesicles

- in blood plasma. J Extracell Vesicles, 2021. 10(11): p. e12140.
- 46. Tian, B.M., et al., Human platelet lysate supports the formation of robust human
- periodontal ligament cell sheets. J Tissue Eng Regen Med, 2018. 12(4): p. 961-972.
- 47. Mathieu, M., et al., Specificities of exosome versus small ectosome secretion
- revealed by live intracellular tracking of CD63 and CD9. Nat Commun, 2021. 12(1): p. 4389.
- 48. Martínez-Beamonte, R., et al., Sphingomyelin in high-density lipoproteins: structural
- role and biological function. Int J Mol Sci, 2013. 14(4): p. 7716-41.
- 49. Sódar, B.W., et al., Low-density lipoprotein mimics blood plasma-derived exosomes
- and microvesicles during isolation and detection. Sci Rep, 2016. 6: p. 24316.
- 50. Izzo, C., F. Grillo, and E. Murador, Improved method for determination of high-
- 849 density-lipoprotein cholesterol I. Isolation of high-density lipoproteins by use of polyethylene
- glycol 6000. Clin Chem, 1981. 27(3): p. 371-4.
- 51. Simonsen, J.B., What Are We Looking At? Extracellular Vesicles, Lipoproteins, or
- 852 Both? Circ Res, 2017. 121(8): p. 920-922.

853

# 854 Figures

855 Figure 1: A methodological overview. Platelet poor plasma was obtained from healthy 856 volunteers (n=4) and patients presenting with myocardial infarction (MI) (n=6) (and from the 857 same patients 1-month post-MI) and plasma extracellular vesicles (EV) isolated using five 858 different methods: ultracentrifugation (UC), precipitation, acoustic trapping, size exclusion 859 chromatography (SEC) and immunoaffinity capture with a matched vehicle phosphate 860 buffered saline (PBS) or IgG control. The plasma EV were analyzed using Nanoparticle 861 Tracking Analysis, protein concentration, Western blot, transmission electron microscopy, a 862 targeted EV-protein array for EV-markers CD9, CD63, CD81, ALIX, TSG101, flotillin, 863 Annexin V and 18 other cell associated markers, untargeted proteomics (LC-MS/MS) and 864 targeted sphingolipidomics (LC-MS/MS). The data were analyzed in insolation and following 865 integrated hierarchical clustering and principal component analysis.

866

867 Figure 2: Plasma EV characterization using different isolation methods. (A) Total 868 plasma extracellular vesicles (EV) / mL concentrations and (B) size and concentration 869 distribution profiles were obtained by Nanoparticle Tracking Analysis (NTA) using 870 ultracentrifugation (UC), precipitation, acoustic trapping, size exclusion chromatography 871 (SEC) and immunoaffinity capture (n=4). Values are presented as a delta compared to a 872 vehicle control or IgG control. Scale is logarithmic. (C) Protein concentration of plasma EV 873 using UC, precipitation, acoustic trapping, SEC and immunoaffinity capture (n=4). Values 874 are presented as a delta compared to a vehicle control or IgG control. (D) Western blot of 875 plasma EV derived from UC, precipitation, acoustic trapping, SEC and immunoaffinity 876 capture versus controls using EV markers ALIX and CD63, lipoprotein contaminants 877 apolipoprotein B (ApoB), and apolipoprotein A-I (ApoA-I), plasma contaminant albumin and 878 cellular contaminant histone H3. Endothelial cell EV and Peripheral blood mononuclear cells 879 (PBMCs) were used for H3 positive controls. (E-J). Transmission electron microscopy (TEM) 880 images of isolated plasma EV from UC, precipitation, acoustic trapping, SEC and 881 immunoaffinity capture versus controls. Each sub panel contains a zoomed-in image (left

34

image), an overview image (top right) and a control vehicle image (bottom right). For the immunoaffinity bead capture images, the red arrows indicate EV particles. The scale bar is 200 nm for the zoomed images surrounded by a dashed line and 1000 nm for the overview images and **J**. Values in **A** and **C** are group average  $\pm$  standard deviation (SD). Data are group average  $\pm$  standard deviation (SD) (n=6).

Data was analyzed by one-way ANOVA with post-hoc Bonferroni correction. \*\*\*p<0.001.

888

889 Figure 3: Heatmap of plasma EV derived from different isolation methods using the 890 EV- protein-Array. The heatmap contains extracellular vesicles (EV) markers CD9, CD81, 891 CD63, ALIX, TSG101, Flotillin 1 and Annexin V for ultracentrifugation (UC), precipitation, 892 acoustic trapping, size exclusion chromatography (SEC) and immunoaffinity capture, lipid 893 contaminants apolipoprotein H (ApoH) and apolipoprotein E (ApoE) and cell associated 894 markers. Values are presented as a delta compared to a vehicle control or IgG control and 895 are log normalized (n=4 per isolation method). Data was analyzed by Krusalski-Wallis test 896 with post-hoc Bonferroni correction. \*p<0.05, \*\*\*p<0.001.

897

898 Figure 4: Proteomic comparison of plasma EV isolation methods. (A) The number of 899 protein groups quantified by unbiased proteomics for plasma extracellular vesicles (EV) 900 derived by: ultracentrifugation (UC), precipitation, acoustic trapping, size exclusion 901 chromatography (SEC) and immunoaffinity capture, versus control vehicle (PBS) or an IgG 902 control. Protein groups were only included as quantified if they had ≥2 unique peptides. 903 (n=3-4). One-way ANOVA with post-hoc Bonferroni correction. Data are group averages ± 904 standard deviation (SD). \*p<0.05, \*\*\*p<0.001. (B) A heatmap of the top 30 quantified protein 905 groups across all isolation methods. Values from control samples were subtracted to 906 account for background and the values were log normalised. Hierarchical clustering of the 907 isolation methods was conducted using a complete clustering method. (n=3-4).

908

35

#### 909 Figure 5: Sphingolipidomic analysis of plasma EV from different isolation methods.

910 (A) Number of sphingolipids quantified in plasma extracellular vesicles (EV) isolated by 911 ultracentrifugation (UC), precipitation, acoustic trapping, size-exclusion chromatography 912 (SEC) and immunoaffinity capture and subjected to targeted sphingolipid analysis versus 913 control vehicle (PBS) or an IgG control. Data are group averages ± standard deviation (SD) 914 and were analysed by One-way ANOVA with post-hoc Bonferroni correction. \*\*\*p<0.001. 915 (n=4) (B) Heat map of plasma EV sphingolipids. Values from control samples were 916 subtracted to account for background and the values were log normalised. Hierarchical 917 clustering of the isolation methods was conducted using a complete clustering method. (n=3-918 4). Data were analysed by Krusalski-Wallis test with post-hoc Bonferroni correction.

919

920 Figure 6: Principal component analysis of plasma EV characteristics following data 921 integration. (A) A principal component (PC) analysis of plasma extracellular vesicles (EV) 922 isolated by ultracentrifugation (UC), precipitation, acoustic trapping, size-exclusion 923 chromatography (SEC) and immunoaffinity capture: including plasma EV concentration, 924 protein concentration, EV-protein-Array, proteomics and sphingolipidomics. The integrated 925 data was condensed to PC1 and PC2. (B) A heatmap with the various principal components 926 to compare the different isolation plasma EV isolation methods. Hierarchical clustering of the 927 isolation methods was conducted using a complete clustering method. (n=3-4).

928

929 Figure 7: Plasma EV analysis using different isolation methods in patients following 930 presentation with myocardial (MI) infarction compared to samples from the same 931 patients after a 1-month follow up. (A) Comparison of concentration and size-distribution 932 profile by Nanoparticle Tracking Analysis of plasma extracellular vesicles (EV) from patients 933 following presentation with MI and after a 1-month follow up using: ultracentrifugation (UC), 934 precipitation, acoustic trapping, size exclusion chromatography (SEC) and immunoaffinity 935 capture (n=6 per timepoint). Data are group average ± standard deviation (SD). Paired T-936 test analysis \*p<0.05. (B) A Pearson correlation analysis of plasma EV / mL derived from

36

937 each isolation method at time of presentation vs. the infarct size determined by cardiac MRI 938 using late gadolinium enhancement 6-months post-infarct (n=5). (C) Heatmap of plasma EV-939 Array analysis. The top section of the heatmap contains the different EV markers CD9, 940 CD81, CD63, ALIX, TSG101, Flotillin 1 and Annexin V. Values are presented as fold over 941 the respective matched follow up control sample. (D) Heatmap showing the plasma EV 942 sphingolipidomic profiles in MI patents at presentation versus a 1-month follow up for UC, 943 precipitation, acoustic trapping, SEC and immunoaffinity capture. Values are presented as 944 fold over the respective matched follow up.

945

946 Figure 8: Principal component analysis of integrated plasma EV characterisation at 947 time of presentation with myocardial infarction (MI) vs. 1-moth follow-up in the same 948 patients using different plasma EV isolation methods. A principal component (PC) 949 analysis of plasma EV isolated by ultracentrifugation (UC), precipitation, acoustic trapping, 950 size-exclusion chromatography (SEC) and immunoaffinity capture from patients presenting 951 with MI versus a 1-month follow up control. Plasma EV characteristics include including 952 plasma EV concentration, protein concentration, EV-protein-Array and sphingolipidomics. 953 The integrated data was condensed to PC1 and PC2. (n=5-6). The eclipses indicate the 954 95% confidence interval.

955

# 956 Tables

Table 1: Nanoparticle Tracking Analysis showing the mean and median size of plasma- EV isolated by ultracentrifugation (UC), precipitation, acoustic trapping, sizeexclusion chromatography (SEC). Immunoaffinity capture can not be acquired. Data are group averages  $\pm$  standard deviation (SD) and were analyzed by One-way ANOVA with post-hoc Bonferroni correction. \*\*\*p<0.001. (n=4).

962

Table 2: Clinical characteristics of the MI patients. Age, sex (M/F), glucose, white blood cells counts, troponin peak, cholesterol, diabetes status, smoker status, infarct size determined by late gadolinium enhancement MRI 6 months post-AMI and left ventricle ejection fraction (LVEF %) 6 moths post-MI. Data are group averages ± standard deviation (SD) (n=6).

38

# 968 Supplemental Figures

Supplemental Figure 1: The ratio of plasma extracellular vesicles (EV) to protein concentration per isolation method: ultracentrifugation (UC), precipitation, acoustic trapping, size-exclusion chromatography (SEC) and immunoaffinity capture. EV are expressed as per mL and protein concentration is expressed  $\mu$ g. Values are expressed as delta over phosphate buffer solution (PBS) control or IgG control. Data are group averages ± standard deviation (SD) (n=4). One-way ANOVA with post-hoc Bonferroni correction. \*\*p<0.01, \*\*\*p<0.001.

976

977 Supplemental Figure 2: Venn diagram of quantified protein groups in different plasma 978 extracellular vesicle (EV) isolation methods: ultracentrifugation (UC), precipitation, 979 acoustic trapping, size-exclusion chromatography (SEC) and immunoaffinity capture. 980 Quantified protein groups within a method were pooled after subtraction of phosphate buffer 981 solution (PBS) control or IgG control. Protein groups that had more than 1 repeat within a 982 method were included in the Venn diagram.

983

984 Supplemental Figure 3: Gene Ontology analysis of plasma extracellular vesicle (EV) 985 isolation method proteomics: ultracentrifugation (UC), precipitation, acoustic trapping, 986 size-exclusion chromatography (SEC) and immunoaffinity capture. (A) Quantified protein 987 groups were expressed as delta over phosphate buffer solution (PBS) control or IgG control. 988 Quantified protein groups that appeared more than once per method were included in the 989 Gene Ontology (GO) analysis. The GO cellular components associated with each method 990 were ranked based on the false discovery rate (FDR) and the top five were included in the 991 tables. In addition, the GO enrichment scores were plotted against the false discovery rate p-992 values in the scatterplot. (B) The overlap between quantified protein groups per plasma EV 993 isolation method and published EV proteomics databases EVpedia, Exocarta and 994 Vesiclepedia. The table contains the percentage of overlapping protein groups vs. total 995 protein groups per isolation method, with a p-value calculated by fisher-exact test.

39

996

997 Supplemental Figure 4: The overlap between the number of quantified protein groups 998 per plasma extracellular vesicle (EV) isolation method and published plasma EV 999 proteomic datasets. Quantified protein groups within a method were pooled after 1000 subtraction of phosphate buffer solution (PBS) control or IgG control. Protein groups that had 1001 more than 1 repeat within a method were included. Plasma EV-proteomes determined by 1002 ultracentrifugation (UC), precipitation, acoustic trapping, size-exclusion chromatography 1003 (SEC) and immunoaffinity capture were compared with published EV proteomic datasets. 1004 The overlap of protein groups between each method were compared and listed out of the 1005 total protein groups quantified.

1006

1007 Supplemental Figure 5: Venn diagram showing the overlap between quantified 1008 sphingolipids in different plasma extracellular vesicles (EV) isolation methods: 1009 ultracentrifugation (UC), precipitation, acoustic trapping, size-exclusion chromatography 1010 (SEC) and immunoaffinity capture. Sphingolipids within a method were pooled after 1011 subtraction of phosphate buffer solution (PBS) control or IgG control. Sphingolipids that had 1012 more than 1 repeat within a method were included in the Venn diagram.

1013

1014 Supplemental Figure 6: Scree plots of each principal component following the integrated data analysis of plasma extracellular vesicle (EV) isolated with the different 1015 1016 methods: ultracentrifugation (UC), precipitation, acoustic trapping, size-exclusion 1017 chromatography (SEC) and immunoaffinity capture. Data from the acquired unbiased 1018 proteomics, targeted sphingolipidomics, EV-Array analysis and concentration/size analysis 1019 was pooled for each isolation method. Principal components were generated with the R-1020 package Factoextra and FactoMineR. Each scree plot indicates the percentage of variance 1021 explained for the principal component and the top 30 drivers for the principal component. 1022 Data was labelled based on the origin; Lipid indicates data from the targeted sphingolipid

40

data, EV indicates data from the EV-protein-array and unlabeled was selected for data fromthe proteomics.

1025

1026 Supplemental Figure 7: Plasma extracellular vesicle (EV) concentration and size 1027 characteristics after isolation from myocardial infarction (MI) patients at time of 1028 presentation and one month follow up. (A) The variance of plasma EV concentration 1029 isolated by each method measured by Nanoparticle Tracking Analysis (NTA). The variance 1030 was calculated by relative standard deviation over three different measurements. Values are 1031 expressed as delta over phosphate buffer solution (PBS) control or IgG control. (B) The 1032 average size of the isolated plasma EV for each method at time of presentation vs. follow up 1033 measured by NTA. Immunoaffinity capture can not be acquired. (C) Size distribution profiles 1034 of the plasma EV from MI patients at time of presentation and one month follow up. 1035 Immunoaffinity capture can not be acquired. Data are group averages ± standard deviation (SD) (n=12 for A, n=6 for B, n=6 per time point for C). One-way ANOVA with post-hoc 1036 1037 Bonferroni correction. \*p<0.05 for A and B.

1038

Supplemental Figure 8: Sphingolipid concentrations of plasma extracellular vesicles (EV) isolated by different methods: ultracentrifugation (UC), precipitation, acoustic trapping, size-exclusion chromatography (SEC) and immunoaffinity capture. The fold change in sphingolipid concentration in plasma EV isolated at time of presentation with myocardial infarction (MI) versus the concentration in plasma EV isolated 1-month post-MI per isolation method. Data are group averages  $\pm$  standard deviation (SD) and were analysed by one-way ANOVA with post-hoc Bonferroni correction. \*p<0.05 and \*\*p<0.01. (n=5-6)

1046

Supplemental Figure 9: Plasma extracellular vesicle (EV) sphingolipid concentration correlation with infarct size. A Pearson correlation analysis was conducted with the the fold change in sphingolipid (A: Cer(d18:0/22:0) ; B: sphinganine (d18:0) ; C: SM(d18:1/18:1) concentration in plasma EV isolated at time of presentation with myocardial infarction (MI)

41

- 1051 versus the concentration in plasma EV isolated 1-month post-MI by the precipitation method
- 1052 versus the infarct size determined by cardiac MRI using late gadolinium enhancement 6-
- 1053 months post-infarct (n=5).

# Figure 1





# **Data integration**





SEC

IgG control



Immunoaffinity



# Figure 3







В





В







Figure 8



medRxiv preprint doi: https://doi.org/10.1101/2022.04.12.22273619; this version posted April 16, 2022. The copyright holder for this prep (which was not certified by peet@eview) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights preparity of reuse allowed without permission.



# Table 1

	Mean size (nm)	Median size (nm)	
***Ultracentrifugation	143.7 ± 3.4	125.0 ± 2.9	
medRxiv <b>Pape rightstrojn</b> oi (which was not centilied by pe	org/10.1101/2022014.52.42276619; this version er review) is the author/funder, who has granted All rights reserved. No reuse allowed w	posted Appyint 6-1-20-227 The cop ImedRxiv a license to display ithout permission.	yright holder for this pre he preprint in perpetuity
Acoustic trapping	81.2 ± 3.9	70.7 ± 4.6	
SEC	87.2 ± 1.5	75.0 ± 1.4	
Immunoaffinity	-	-	

# Table 2

		Average ± SD	
	Age	67.0 ± 11.4	
medRxiv p (which	reprint doi: <b>Sex/(male/female)</b> 22.04.12.22 was not certified by peer review) is the author/fur All rights reserved Glucose (mmol/L)	273619; this version p <b>6/9</b> d April 16, 2022. The o der, who has granted medRxiv a license to displa . No reuse allowed without permission. 5.7 ± 0.5 (N=3)	opyright holder for this prep y the preprint in perpetuity.
	White blood cell count (x10^9)	7.6 ± 2.2	
	Troponin (peak ng/L) at presentation	358.7 ± 401.2	
	Cholesterol (mmol/L)	4.8 ± 1.2	
	Diabetic status (diabetes / non)	0/6	
	Smoker status (smoker / non)	1/5	
	Infarct size at 6-months	15 ± 7.8	
	LVEF at follow up (%)	47 ± 5.0	